Figure 1.
Flow chart of study population.
Table 1.
Characteristics of 2990 adults with pre-treatment body weight.
Figure 2.
Consistency with Taiwan Guidelines in prescribing Rifater.
Figure 3.
Consistency with recommended dosage in mg/kg body weight for Rifampicin 8–10 mg/kg), Isoniazid (4–6 mg/kg), and pyrazinamide (20–30 mg/kg) among those prescribed Rifater.
Figure 4.
Consistency with recommended dosage in mg/kg body weight for Rifampicin 8–10 mg/kg) and Isoniazid (4–6 mg/kg) among those prescribed Rifinah150.
Figure 5.
Consistency with Taiwan Guidelines in prescribing Rifampicin.
Figure 6.
Consistency with Taiwan Guidelines in prescribing Isoniazid.
Figure 7.
Consistency with Taiwan Guidelines in prescribing Pyrazinamide.
Table 2.
Factors associated with inadequate dosing of rifampin among patients treated with Rifater, Rifinah, or Rifampicin in single-drug preparation, 2007–2010, Taipei.
Table 3.
Factors associated with inadequate dosing of isoniazid among patients treated with Rifater, Rifinah or isoniazid in single-drug preparation, 2007–2010, Taipei.
Table 4.
Factors associated with inadequate dosing of pyrazinamide among patients treated with Rifater or pyrazinamide in single-drug preparation, 2007–2010, Taipei.
Figure 8.
Consistency with Taiwan Guidelines in prescribing Ethambutol.
Table 5.
Factors associated with inadequate dosing of ethambutol, 2007–2010, Taipei.